Last updated: 2026-09-09 10:37:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Immunome, Inc. (IMNM) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $26.36, with a market capitalization of $3.04B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $8.67 to $30.06. This page covers its latest market performance, valuation, price trends and company information.
$3.04B | |
$26.63 | |
$63.78 | |
$2.09 | |
$26.81 | |
519.00 | |
1.34M | |
-- | |
$30.06 | |
$8.66 | |
-- | |
-- |
Immunome, Inc. (IMNM) is trading at $26.36 in pre-market trading as of 2026-09-09 10:00:00, down 1.68% ($0.45) from the previous close of $26.81
Pre-market trading shows how investors are pricing IMNM before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Immunome, Inc. (IMNM) moved from $27.57 to $26.36, representing a decline of 4.39% ($1.21).
The stock traded between $25.91 and $28.77 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 790.57 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 82.7%
IMNM is currently trading at $26.36, placing it 82.7% of the way from its 52-week low of $8.67 to its 52-week high of $30.06. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 177 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Immunome, Inc. (IMNM) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.